Screening research of evaluating methods for lymph node involvement in stage I endometrial cancer

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000038018

Enrollment

Unknown

Registered

2020-09-08

Start date

2020-11-01

Completion date

Unknown

Last updated

2020-11-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometrium cancer

Interventions

Gold Standard:Pathology analysis

Index test:Myo&#32

rule,ESO&#32

rule,Gog99&#32

rule.SLN&#32

lymph&#32

node&#32

detection

Eligibility

Sex/Gender

Female

Age

25 Years to 69 Years

Inclusion criteria

Inclusion criteria: Patients with stage I endometrial carcinoma assessed preoperatively.

Exclusion criteria

Exclusion criteria: 1. Patients with special pathological types, such as plasma breast cancer; 2. Patients who have received pelvic radiotherapy; 3. Patients who can not tolerate surgery.

Design outcomes

Primary

Measure	Time frame
lymph node pathology analysis;SEN, SPE, ACC, AUC of ROC, PPV, NPV;	—

Countries

China

Contacts

Public ContactWei Li

Beijing Maternity Hospital Affiliated to Capital Medical University

mengfq75@163.com+86 17744569485

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026